Researchers from the Perelman School of Medicine at the University of Pennsylvania and the Penn Center for AIDS Research (CFAR) are among the 2015 recipients of the prestigious Clinical Research Achievement Award for their personalized gene therapy work in HIV.
Health & Medicine
Like a beloved pair of jeans, human DNA accumulates damage over time, and older people’s bodies can’t repair it as well. Many scientists believe a build up of damage can cause cells to enter an irreversible dormant state known as senescence.
Two Penn Medicine Studies Examine Diabetes Severity in Parkinson's, Sex Differences in Parkinson's Disease Caregiving
A pair of studies from the Perelman School of Medicine at the University of Pennsylvania demonstrate a correlation between diabetes severity and parkinsonism, or parkinsonian tremors; and examine the caregiving differences between men and women with PD.
Penn Study Shows Computer-Assisted Diagnosis Tool Helps Physicians Assess Skin Conditions Without Aid from Dermatologists
In the first major study to examine the use of a computer-assisted, photo-driven differential diagnosis generator for skin conditions, researchers at the Perelman School of Medicine at the University
The brain is a privileged organ in the body. So vital to life, the brain is protected from alterations elsewhere in the body by a highly regulated gateway known as the blood-brain barrier, which allows only selected molecules to pass through.
Plasma Ap0A1 Associates with Age at Onset and Motor Severity in Early Parkinson’s Disease Patients, Penn Medicine Researchers Find
Building on previous research showing that plasma Apolipoprotein A1 (ApoA1) may be a useful biomarker for Parkinson’s disease, researchers from the Perelman School of Medicine at the Universit
Penn Medicine Researchers Introduce New Brain Mapping Model Which Could Improve Effectiveness of Transcranial Magnetic Stimulation
Brain researchers from the Perelman School of Medicine at the University of Pennsylvania have developed a new brain mapping
Immunotherapy Drug Pembrolizumab Shows Early Promise for Mesothelioma Patients, Penn Medicine Researchers Find
The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall, according to a new study from researchers in the
New Combination of Immunotherapy Drugs is Safe, Shrinks Tumors in Metastatic Melanoma Patients, Penn Study Finds
Once again, researchers at Penn’s Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.
Penn Medicine: Investigational Personalized Cellular Therapy Tolerated Well by Patients with Advanced Mesothelioma, Ovarian and Pancreatic Cancers
Genetically modified versions of patients’ own immune cells successfully traveled to tumors they were designed to attack in an early-stage trial for mesothelioma and pancreatic and ovarian cancers at the Per